Figure 4 | Scientific Reports

Figure 4

From: Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins

Figure 4

Tetramerized H4 and B38 anti-SARS-CoV-2 antibodies are potent inhibitors of virus infection. The viral infection neutralizing potency of tetrameric versions of the mAbs H4 and B38 was examined in SARS-CoV-2 pseudovirus infection assays. Increasing concentrations of H4-scFv-TD, H4-Fab-TD or B38-Fab-TD were incubated with HEK 293 T/17-A2-T2 cells after 1 h. The cells were incubated for 60 h before luciferase activity, indicative of viral entry, was determined. The efficacy was compared to the neutralization effects of a commercial anti-SARS-CoV-2 mAb SAD-S35 (AcroBiosystems) and a tetramerized ACE2-Fc-TD. Data are represented in µg/mL (A) and nM (B). Calculated IC50 values are tabulated below each set of curves. The assays were performed twice, in duplicate with error bars indicating the standard error.

Back to article page